Pune, India., June 01, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Organoids Market Size Report, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Application, Source, and Geography”, the global organoids market size is expected to grow from USD 2.50 billion in 2022 to USD 8.12 billion by 2028; it is estimated to record a CAGR of 21.8% from 2023 to 2028.
Download PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00017616
Organoids Market Report Scope, Segmentations, Regional & Country Scope:
| Report Coverage | Details |
| Market Size Value in | USD 2,507.28 million in 2022 |
| Market Size Value by | USD 8,121.45 million by 2028 |
| Growth rate | CAGR of 21.8% from 2023 to 2028 |
| Forecast Period | 2023-2028 |
| Base Year | 2022 |
| No. of Pages | 196 |
| No. of Tables | 83 |
| No. of Charts & Figures | 80 |
| Historical data available | Yes |
| Segments covered | Type, Application, Source, and Geography |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Companies Covered | STEMCELL Technologies, Cellesce, Hubrecht Organoid TechnologY, Definigen , Organoid Therapeutics, PeproTech, Inc, Thermo Fisher Scientific Inc , Corning Inc, Merck KGaA, InSphero |
Browse key market insights spread across 196 pages with 83 list of tables & 80 list of figures from the report, "Organoids Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), Source (Pluripotent Stem Cells and Organ-specific Adult Stem Cells), and Geography" in detail along with the table of contents: https://www.theinsightpartners.com/reports/organoids-market
Global Organoids Market: Competitive Landscape and Key Developments
STEMCELL Technologies Inc; Cellesce Ltd; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; PeproTech, Inc; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA, and InSphero are a few of the key companies operating in the organoids market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name. A few of the recent developments in the global organoids market are mentioned below:
In May-2020, UK-headquartered iPSC disease modeling company DefiniGEN has identified iPSC-derived intestinal organoids that could be used to help structure in vitro studies of the biology of SARS-CoV2 infection across cohorts of multiple patients.
In March-2023, Molecular Devices, LLC. and HUB Organoids (HUB), announced a strategic collaboration enabling continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition. Under the terms of the agreement, Molecular Devices will license cutting-edge HUB Organoid Technology to work with patient-derived intestinal organoids, expanding Molecular Devices’ 3D biology expertise beyond organoid types like the heart and brain.
In Feb-2023, Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers. The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance
Speak to Research Expert: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00017616
Organoids are extremely small, self-organized, three-dimensional tissue cultures that are derived from stem cells. Such cultures can be crafted to replicate much of the complexity of an organ or to express selected aspects of it, like producing only certain types of cells. Organoids grow from stem cells—cells that can divide indefinitely and produce different types of cells as part of their progeny. Organoids can range in size from less than a hair's width to five millimeters.
Growing Adoption of Personalized Drugs to Fuel Organoids Market Growth During Forecast Period:
Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years. According to the latest report by the PMC (published in 2021), in the US, the number of personalized medicines in the market has risen from 132 in 2016 to 286 in 2020. The data was shared by tracking the numbers of personalized medicine since 2008 by the PMC.
The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.
Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPRE00017616
Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcomes.
Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.
As per the International Society of Aesthetic Plastic Surgery report, US$ 16.7 billion were spent on cosmetic procedures in the US, and South Atlantic recorded the highest number of cosmetic procedures performed in the US with about 3.8 million (25%) procedures in 2020. Furthermore, a report by the Cleveland Clinic Foundation states that liposuction is the second most commonly performed cosmetic surgery and surgical procedure performed in patients from the age group of 35–64 in the US. Short surgery time (typically under 3 hours) and recovery period, unobstructed scars, permanent results, and low complication and morbidity rates are a few of the advantages of liposuction over other surgical procedures.
Buy Premium Copy of Organoids Market Growth Report (2023-2028) at: https://www.theinsightpartners.com/buy/TIPRE00017616
Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):
Human Liver Models Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Stomach Cancer Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Laboratory Animal Model Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Mice Model Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Humanized Mice Model Market Forecast to 2028 - COVID-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/organoids-market
Industry Research: https://www.biospace.com/employer/2735308/the-insight-partners/
